Home » Healthcare » Digestive and Intestinal Remedies Market
Digestive and Intestinal Remedies Market By Type (Digestive Medicines, Remedies Against Gastrointestinal Complaints); By Age Group (Adult, Pediatric); By Distribution Channel (Offline, Online); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Digestive and Intestinal Remedies Market size was valued USD 19,545 million in 2024 and is anticipated to reach USD 26,852 million by 2032, at a CAGR of 4.05% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Digestive and Intestinal Remedies Market Size 2024
USD 19,545 Million
Digestive and Intestinal Remedies Market, CAGR
4.05%
Digestive and Intestinal Remedies Market Size 2032
USD 26,852 Million
The digestive and intestinal remedies market is led by prominent companies including Pfizer Inc., Johnson & Johnson, Menarini Group, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG., Merck & Co, Inc., Bayer AG, GlaxoSmithKline plc, China Resources Pharmaceutical Group Limited, and Abbott Laboratories. These players dominate through broad product portfolios covering antacids, probiotics, and enzyme-based formulations. Continuous R&D investment and expansion of OTC and prescription drug lines strengthen their global presence. North America leads the market with a 38% share, supported by advanced healthcare infrastructure, strong retail pharmacy networks, and early adoption of innovative digestive health solutions.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The digestive and intestinal remedies market was valued at USD 19,545 million in 2024 and is expected to reach USD 26,852 million by 2032, growing at a CAGR of 4.05%.
Rising prevalence of digestive disorders and growing awareness of gut health drive market demand across all major regions.
Increasing preference for herbal and probiotic-based formulations is shaping product innovation and consumer trends.
The market remains competitive with leading players expanding OTC and prescription drug portfolios to strengthen global presence.
North America leads with a 38% market share, while digestive medicines hold the dominant segment share due to strong demand for enzyme-based and antacid solutions.
Market Segmentation Analysis:
By Type
The digestive and intestinal remedies market is segmented into digestive medicines, remedies against gastrointestinal complaints, and natural and synthetic agents. Digestive medicines dominate the segment with a market share of 46%, driven by the high prevalence of indigestion, acidity, and bloating disorders. Increased availability of enzyme-based and probiotic formulations also supports their growth. Johnson & Johnson’s Pepcid and Abbott’s Creon enzymes have seen strong adoption in both prescription and OTC channels. Continuous innovation in fast-acting antacids and combination enzyme products further enhances the dominance of this sub-segment.
For instance, Johnson & Johnson’s product **PEPCID® (famotidine) — available in 20 mg and 40 mg tablets — achieved mean nocturnal gastric acid inhibition of 86 % with the 20 mg dose and 94 % with the 40 mg dose over at least a 10-hour period.
By Age Group
Adults account for the dominant share of 64% in the market, primarily due to lifestyle-related gastrointestinal issues such as acid reflux, constipation, and irritable bowel syndrome. The increasing consumption of processed foods, sedentary behavior, and stress contribute to higher digestive disorder prevalence in adults. Bayer’s Iberogast and Sanofi’s Buscopan target adult consumers with recurrent stomach and intestinal discomfort. The pediatric segment is also growing steadily, supported by improved diagnosis and awareness of digestive health in children.
For instance, Menarini Group conducted its OBIS study on its own molecule Otilonium Bromide in adults with irritable bowel syndrome, where treatment over 15 weeks was followed by sustained efficacy up to 10 weeks post-treatment.
By Distribution Channel
Offline distribution channels, including pharmacies and hospital dispensaries, hold the largest market share of 71%, as consumers prefer direct pharmacist consultations and immediate product availability. The segment benefits from wide product accessibility and physician recommendations for prescription-based remedies. GlaxoSmithKline’s Eno and Reckitt’s Gaviscon remain top-selling products across offline retail outlets. However, the online channel is witnessing rapid growth due to increasing e-commerce penetration, discount offers, and growing consumer trust in digital pharmacy platforms.
Key Growth Drivers
Rising Prevalence of Digestive Disorders
The growing incidence of gastrointestinal diseases such as acid reflux, irritable bowel syndrome, and ulcers is driving market expansion. Increasing unhealthy eating habits, stress, and sedentary lifestyles have led to greater dependence on digestive medicines and enzyme-based products. For instance, Abbott’s Creon and Sanofi’s Maalox have witnessed higher prescription rates among patients with chronic digestive issues. The growing elderly population, which is more prone to digestive ailments, further supports market demand across both developed and emerging regions.
For instance, Eli Lilly and Company’s biologic therapeutic Omvoh® (mirikizumab‑mrkz)—approved for adults with moderately to severely active Ulcerative Colitis—offers a 200 mg/2 mL once-monthly subcutaneous injection regimen.
Increased Consumer Awareness of Gut Health
Rising awareness of the importance of gut microbiota in overall health has accelerated the use of probiotics, prebiotics, and natural digestive aids. Consumers are adopting dietary supplements and functional foods to improve digestive well-being and prevent disorders. For instance, Nestlé’s Garden of Life probiotics and Bayer’s Align have seen strong retail growth due to increased preventive health awareness. This shift toward self-care and preventive treatment continues to expand the demand for over-the-counter digestive remedies globally.
For instance, Bayer AG launched its flagship digestive-health product Iberogast, which is backed by more than 20 scientific studies involving over 7,000 patients, thereby reinforcing its evidence-base for gut-microbiome support.
Expansion of Over-the-Counter (OTC) Product Availability
The growing acceptance and regulatory support for OTC digestive remedies are boosting market accessibility. Consumers increasingly prefer non-prescription solutions for mild gastrointestinal issues such as heartburn and constipation. For instance, GSK’s Tums and Reckitt’s Gaviscon remain leading OTC brands due to their proven efficacy and strong retail presence. Expanding distribution networks, combined with aggressive marketing and e-commerce availability, are further strengthening the OTC segment’s contribution to overall market growth.
Key Trends & Opportunities
Shift Toward Natural and Herbal Formulations
Consumers are showing a clear preference for herbal and plant-based digestive products due to safety and fewer side effects. Manufacturers are launching formulations with ingredients like peppermint oil, fennel, and licorice for gastrointestinal relief. For instance, Himalaya’s Liv.52 and Dabur’s Pudin Hara have gained popularity as trusted natural digestive remedies. This trend opens opportunities for companies to innovate in botanical-based solutions and expand into preventive digestive healthcare segments.
For instance, Abbott’s prescription enzyme product CREON (pancrelipase delayed-release capsules) specifies dosage forms including 3,000 USP units of lipase paired with 9,500 protease and 15,000 amylase units.
Technological Integration in Product Formulation
Advancements in pharmaceutical and nutraceutical formulation technologies are enabling the development of targeted-release and combination digestive products. Companies are focusing on controlled-release tablets, enzyme-stabilized capsules, and probiotic microencapsulation for enhanced efficacy. For instance, Procter & Gamble’s Pepto-Bismol reformulations improve absorption rates and user compliance. Such innovations are helping brands strengthen product differentiation while meeting diverse patient needs across demographics.
For instance, DuPont’s probiotics portfolio—branded as HOWARU®—contained over 15 documented bacterial strains optimized for digestive and immune-health applications.
Rising Penetration of Online Pharmacies
The rapid growth of e-commerce platforms is transforming the distribution landscape of digestive and intestinal remedies. Online pharmacies offer convenience, price transparency, and a wide range of options for consumers. For instance, Amazon Pharmacy and 1mg have seen increased orders for antacids and probiotic supplements. This trend provides an opportunity for manufacturers to expand direct-to-consumer channels and enhance accessibility in remote regions.
Key Challenges
Stringent Regulatory and Quality Compliance
Manufacturers face challenges in adhering to complex global regulatory frameworks for both OTC and prescription digestive products. Differences in labeling, clinical validation, and safety testing requirements increase time-to-market and costs. For instance, herbal digestive remedies often face scrutiny from agencies such as the FDA and EMA over standardization and efficacy claims. Maintaining consistent quality while meeting diverse regional regulations remains a significant operational challenge.
Adverse Effects and Product Misuse
Long-term or excessive use of certain digestive remedies, such as laxatives and proton pump inhibitors, can lead to dependency or adverse health outcomes. Consumer misuse of OTC medications without medical supervision adds to the risk of side effects. For instance, chronic use of omeprazole-based products has been linked to nutrient deficiencies and gastrointestinal complications. Such issues highlight the need for better consumer education and stricter product usage guidelines to ensure safe and effective treatment.
Regional Analysis
North America
North America holds the dominant market share of 38% in the digestive and intestinal remedies market, supported by high healthcare expenditure, advanced distribution networks, and strong OTC adoption. The region benefits from the presence of major players such as Johnson & Johnson, Abbott Laboratories, and Bayer AG, which continue to expand their gastrointestinal product lines. Increasing cases of acid reflux, IBS, and lifestyle-related digestive issues further drive product consumption. Consumer preference for fast-acting and enzyme-based solutions strengthens the regional outlook, supported by strong retail pharmacy and e-commerce penetration.
Europe
Europe accounts for 27% of the market share, driven by a well-established healthcare infrastructure and a growing shift toward herbal and probiotic-based digestive remedies. Countries such as Germany, France, and the UK lead the market with strong regulatory support for OTC and natural formulations. Manufacturers such as Sanofi and Reckitt Benckiser dominate the region with brands like Gaviscon and Buscopan. Increasing demand for preventive care and digestive supplements among aging populations continues to support steady regional growth.
Asia-Pacific
Asia-Pacific represents 24% of the global market share and is the fastest-growing region, fueled by rising disposable incomes, urbanization, and growing awareness of gut health. India, China, and Japan lead demand due to higher consumption of antacids and herbal digestive products. Companies like Daiichi Sankyo and Himalaya Wellness are expanding their portfolios to address both traditional and modern healthcare needs. The region’s growing e-commerce sector and government initiatives for healthcare access further boost market penetration and product adoption.
Latin America
Latin America captures 6% of the global share, driven by the increasing prevalence of digestive diseases linked to dietary changes and urban lifestyles. Brazil and Mexico lead the regional market with expanding retail pharmacy networks and growing availability of OTC digestive medicines. Rising health awareness and local manufacturing of affordable antacids and probiotics are strengthening regional supply chains. Companies are focusing on partnerships with domestic distributors to enhance product accessibility and market reach in this developing healthcare landscape.
Middle East & Africa
The Middle East & Africa region holds an 5% market share, primarily supported by expanding healthcare infrastructure and increasing awareness of gastrointestinal health. The UAE and Saudi Arabia are leading markets due to strong consumer demand for branded OTC digestive products. The growing presence of multinational pharmaceutical companies and local herbal remedy producers supports product diversification. As healthcare spending rises and access to pharmacies improves, the region is expected to see gradual but consistent growth in digestive and intestinal remedy consumption.
Market Segmentations:
By Type:
Digestive medicines
Remedies against gastrointestinal complaints
By Age Group:
Adult
Pediatric
By Distribution Channel:
Offline
Online
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Competitive Landscape
The competitive landscape of the digestive and intestinal remedies market features key players such as Pfizer Inc., Johnson & Johnson, Menarini Group, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG., Merck & Co, Inc., Bayer AG, GlaxoSmithKline plc, China Resources Pharmaceutical Group Limited, and Abbott Laboratories. The digestive and intestinal remedies market is highly competitive, characterized by continuous innovation, strong brand positioning, and expanding product portfolios. Companies are investing in advanced formulations such as probiotics, enzyme-based therapies, and herbal remedies to meet diverse consumer needs. The rise in lifestyle-related digestive disorders and growing demand for OTC solutions drive firms to strengthen retail and e-commerce distribution channels. Strategic collaborations, R&D investments, and marketing campaigns focus on improving treatment effectiveness and consumer awareness. The industry also witnesses increased focus on safety, regulatory compliance, and patient-centric approaches to maintain market credibility and long-term growth.
In October 2024, Dulcolax, the laxative brand from Sanofi, launched a new campaign aimed at prioritizing digestive health. The Pooping Princesses initiative seeks to challenge the stigma surrounding constipation, particularly among women. The launch of Dulcolax’s Pooping Princesses campaign is likely to have a significant impact on the Digestive & Intestinal Remedies Market.
In April 2024, Bayer AG introduced Iberogast, is a plant-based digestive relief solution now available in the U.S. This product features a unique blend of six clinically proven herbs designed to harness the benefits of nature. Iberogast offers dual-action support, effectively alleviating occasional digestive discomfort while promoting overall digestive health.
In October 2023, Pfizer received U.S. FDA approval for Velsipity, which is selective sphingosine-1-phosphate receptor modulator taken orally. The oral pill aimed at treating adult patients with moderately to severely active ulcerative colitis highlights Pfizer’s commitment towards new product development and positions itself as a strong competitor in the market.
In August 2023, Herbalife introduced Herbalife V, a new line of plant-based supplements to meet the growing consumer demand for plant-based products, including supplements. These products have obtained certifications such as USDA Organic, verified non-GMO, certified kosher, and certified plant-based and vegan by FoodChain ID.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The research report offers an in-depth analysis based on Type,Age Group, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The market will experience steady growth driven by increasing cases of digestive disorders worldwide.
Rising consumer awareness about gut health will fuel demand for probiotic and enzyme-based products.
Over-the-counter digestive medicines will gain stronger traction due to convenience and easy availability.
Natural and herbal formulations will see higher adoption as consumers prefer safer alternatives.
Digital and e-commerce channels will expand product accessibility and boost online sales.
Pharmaceutical firms will invest more in R&D to develop fast-acting and long-lasting digestive solutions.
Emerging economies will offer lucrative opportunities due to improving healthcare infrastructure.
Technological advances in drug delivery will enhance treatment precision and patient outcomes.
Strategic collaborations and mergers will strengthen product portfolios and market reach.
Preventive digestive care and personalized nutrition will shape the next phase of market expansion.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global Digestive and Intestinal Remedies Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup By Type
6.1. Digestive medicines
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Remedies against gastrointestinal complaints
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity 7. Market Breakup By Age Group
7.1. Adult
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Pediatric
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity 8. Market Breakup By Distribution Channel
8.1. Offline
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Online
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity 9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast 10. SWOT Analysis
10.1. Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats 11. Value Chain Analysis 12. Porter’s Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes 13. Price Analysis 14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Pfizer Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. Johnson & Johnson
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. Financials
14.3.2.4. SWOT Analysis
14.3.3. Menarini Group
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. Financials
14.3.3.4. SWOT Analysis
14.3.4. Eli Lilly and Company
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. Financials
14.3.4.4. SWOT Analysis
14.3.5. C.H. Boehringer Sohn AG & Co. KG.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. Financials
14.3.5.4. SWOT Analysis
14.3.6. Merck & Co, Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. Financials
14.3.6.4. SWOT Analysis
14.3.7. Bayer AG
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. Financials
14.3.7.4. SWOT Analysis
14.3.8. GlaxoSmithKline plc
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. Financials
14.3.8.4. SWOT Analysis
14.3.9. China Resources Pharmaceutical Group Limited
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. Financials
14.3.9.4. SWOT Analysis
14.3.10. Abbott Laboratories
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. Financials
14.3.10.4. SWOT Analysis 15. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for the Digestive and Intestinal Remedies Market, and what is its projected size in 2032?
The market was valued at USD 19,545 million in 2024 and is projected to reach USD 26,852 million by 2032.
At what Compound Annual Growth Rate is the Digestive and Intestinal Remedies Market projected to grow between 2025 and 2032?
The market is expected to grow at a CAGR of 4.05% during the forecast period.
Which Digestive and Intestinal Remedies Market segment held the largest share in 2024?
The digestive medicines segment held the largest share of 46% in 2024.
What are the primary factors fueling the growth of the Digestive and Intestinal Remedies Market?
Rising prevalence of digestive disorders, growing gut health awareness, and increased OTC product accessibility drive market growth.
Who are the leading companies in the Digestive and Intestinal Remedies Market?
Key players include Pfizer Inc., Johnson & Johnson, Merck & Co, Bayer AG, and Abbott Laboratories.
Which region commanded the largest share of the Digestive and Intestinal Remedies Market in 2024?
North America led the market in 2024 with a 38% share.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Companion Animal Rehabilitation Services Market size was valued at USD 577 million in 2024 and is anticipated to reach USD 1,385 million by 2032, at a CAGR of 11.57% during the forecast period.
The Companion Animal Pain Management Market size was valued at USD 1,727 million in 2024 and is anticipated to reach USD 2,753 million by 2032, at a CAGR of 6% during the forecast period.
Companion Animal Healthcare Market size was valued at USD 113,679 million in 2024 and is anticipated to reach USD 195,322 million by 2032, at a CAGR of 7% during the forecast period.
The Companion Animal Ear Infection Treatment Market size was valued at USD 649 million in 2024 and is anticipated to reach USD 1,193 million by 2032, at a CAGR of 7.91% during the forecast period.
The Companion Animal Drugs Market size was valued at USD 23,273 Million in 2024 and is anticipated to reach USD 38,807 Million by 2032, at a CAGR of 6.6% during the forecast period.
The Companion Animal Arthritis Market size was valued at USD 3,091 Million in 2024 and is anticipated to reach USD 5,311 Million by 2032, at a CAGR of 7% during the forecast period.
The Companion Animal Diagnostic Market size was valued at USD 5,336 Million in 2024 and is anticipated to reach USD 10,829 Million by 2032, at a CAGR of 9.25% during the forecast period.
The Androgenetic Alopecia Treatment Market is projected to grow from USD 2,727.27 million in 2024 to an estimated USD 5,123.26 million by 2032, with a compound annual growth rate (CAGR) of 8.2% from 2024 to 2032.
The Animal Pregnancy Kit Market is projected to grow from USD 49.07 million in 2024 to an estimated USD 68.2 million by 2032, with a compound annual growth rate (CAGR) of 4.2% from 2024 to 2032.
The Antifungal drugs market size was valued at USD 13200.74 million in 2024 and is anticipated to reach USD 17115.94 million by 2032, at a CAGR of 3.3% during the forecast period.
The Annuloplasty System Market was valued at USD 407 million in 2024 and is projected to reach USD 611 million by 2032, expanding at a CAGR of 5.2% during the forecast period.
The Animal Vaccines Market was valued at USD 9,000 million in 2024 and is projected to reach USD 15,120 million by 2032, growing at a CAGR of 6.7% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
